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ISSUE 11
Estimated percent increases (in parenth-
eses, Tables 2–5) are highly variable
representing ratios of quantities that
themselves vary substantially. As such,
it would be helpful to see confidence
intervals reported (including allowance
for between-experiment variation). This
issue arises in the Abstract, where
estimated percent increases are reported
without uncertainty information. This is
particularly crucial as quite different
increases (or decreases) arise with a
different ‘‘control’’ comparison. For ex-
ample, the appropriate average number
of tumors per mouse (if tumors occur—
see above) for the Eucerin group (Experi-
ment 2) is 7.43, and 8.04 for the
Untreated group of Experiment 1. This
‘‘just-as-appropriate’’ comparison yields
a decrease in number of tumors per
mouse of 8%, not the increase of 24%
reported in the Abstract.
ISSUE 12
Finally, is it not possible that any
apparent difference between treat-
ment groups in the number (volume)
of tumors observed might be because of
effects after at least one tumor has
occurred—the latter attribute barely
varying across groups—rather than aris-
ing from any mutagenic or carcinogenic
effects? This concern reinforces
what other commentators have noted
about the misleading nature of the
article’s title (Ellefson, 2009; Staeb
et al., 2009).
There are many fine experimental
papers in the literature that generate
similar data and that successfully han-
dle most of the issues raised here. See,
for example, the study by Lerche et al.,
2008. Unfortunately, given the con-
cerns raised above, I join previous
correspondents in asserting that the
authors’ interpretations of their results
are not scientifically justifiable.
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TO THE EDITOR
Dr Nicholas P. Jewell expresses several
concerns about our publication ‘‘Tu-
morigenic effect of some commonly
used moisturizing creams when applied
topically to UVB-pretreated high risk
mice’’ (Lu et al., 2008). Many of these
concerns were raised earlier (Ellefson,
2009; Staeb et al., 2009) and answered
(Conney et al., 2009a; Conney et al.,
2009b). We answer Dr Jewell’s con-
cerns as follows:
RESPONSE TO ISSUE 1
All randomizations were carried out
after the completion of the UVB pre-
treatment. It might not be clear or
explicit enough, but we did imply this
order in our paper (Materials and
Methods, descriptions of Experiments
1 and 2) by stating ‘‘In experiment 1,
we treated 60 female SKH-1 mice with
UVB y for 20 weeks. y UVB irradia-
tion was stopped, and half of the mice
were treated with 100 mg Dermabase
once a day, yfor 17 weeks, and the
control group was untreated.’’ A similar
description was given for experiment 2.
We add that this is carried out routinely
in our laboratory, as indicated in our
earlier publications. See Proc Natl Acad
Sci USA 99:12455–12460, 2002 and
Carcinogenesis 28:199–206, 2007 (cited
in our manuscript) as well as other papers
from our laboratory. For experiment 1,
we randomized 58 UVB-pretreated
tumor-free mice (29 in each group). In
experiment 2, we randomized all 210
UVB-pretreated tumor-free mice (30 per
group).
RESPONSE TO ISSUE 2
Although the topical treatment of mice
and the collection of data for Figure 1
were not blinded, they were performed
by a lab technician (J.-G. Xie) who had
no scientific interest in the results. The
histological evaluation of tumors (data
in Tables 2–5) was blinded so that the
histologist did not know which group
or mouse was being evaluated, as we
have performed in earlier studies (see
Carcinogenesis 28:199–206, 2007; cited
in our manuscript).
We should point out that experi-
ments 1 and 2 were similar in their
procedures, but they were not identical.
In fact, they were separated by more
than a year and one was a pilot study,
whereas the other was confirmatory
(see additional response later). Although
Dr Jewell believes there was variation
between our two experiments, both
experiments demonstrated a tumorigenic
effect of Dermabase in UVB-pretreated
mice (discussed later).
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RESPONSE TO ISSUE 3
A small number of mice died during
intervention period 2 (most without
tumors), as is often the case for long
longitudinal studies. Our longitudinal
data analysis included all the data
collected before death without any
deletion of these mice. It is common
in this type of study for a small number
of UVB-pretreated mice to die from
unknown causes unrelated to tumor
formation (see Lou et al. (1999) Nutr
Cancer 33:146–153; Lu et al. (2002) Proc
Natl Acad Sci USA 99:12455–12460; Lu
et al. (2007) Carcinogenesis 28:199–206;
cited in our manuscript). The small
number of deaths that occurred in these
and in our current study did not influ-
ence our overall conclusions.
RESPONSE TO ISSUE 4
The ‘‘percent mice with tumors’’ in
Figure 1(a–d) were the raw data, usually
understood by biologists who conduct
this type of animal tumor growth experi-
ment. They were not the Kaplan–Meier
estimates of cumulative incidence of
tumors. As Dr Jewell noticed, if they
were, they would always be increasing
curves. But they were not. The raw data
indicated that although the tumor in-
cidence increased with time for all
groups during the 17 weeks (Figure 1),
there was a small decrease in incidence
(possibly related to regression of some
tumors) over a short 3-week interval in
two groups (untreated and Dermovan
groups). That is, some tumors regressed
and reappeared again. Kaplan–Meier’s
method was used to analyze the time to
the first tumor appearance, and, as
indicated in the Materials and Methods
section as well as in the footnote of
Figure 1, the log-rank test was used to
compare the tumor-free distributions
between the treated and the control
groups. Kaplan–Meier curves were not
shown in the paper because of space
limitations. Instead, the P-values from
the log-rank test were shown. The
decrease in tumor incidence over a
short-time interval did not influence the
overall analyses by the log-rank test or
the Kaplan–Meier estimate of cumulative
incidence.
Concerning the differences between
the plotted numbers in Figure 1c and
Table 4, it should be emphasized that
the data in Figure 1 displays the visual
examination data by longitudinal
graphs while the tables are summaries
of the histological data obtained when
the mice were killed at the last week
(Week 17). Although there is general
agreement between Figure 1 (visually
observed tumors) and the histology data
in the tables, it is well recognized that
exact agreement will not occur because
some of the visually identified tumors
were not verified by histology and some
additional tumors were identified dur-
ing the histological examination.
RESPONSE TO ISSUE 5
Dr Jewell is right that the P-values given
in Figure 1 for the ‘‘percent of mice
with tumor’’ were calculated by the
log-rank test on the tumor-free distribu-
tions between the treated and the
control groups, as was noted in the
footnote to Figure 1 (see response to
Concern 4). Dr Jewell is also right in
noticing that at Week 17, tumor
incidence rates were high (reaching
above 75%) in both groups. That was
because the mice were UVB-pretreated
high-risk mice. We know that even-
tually, as in a time-to-death survival
analysis, all animals will die if we
observe them long enough. But this fact
does not exclude the possibility of
distinguishing two distinct groups. The
standard w2-test at Week 17 performed
by Dr Jewell was not a time-to-event
analysis. Although Kaplan–Meier’s esti-
mates of the cumulative incidence rates
were not shown in our publication, one
can still observe from the raw data
graphs (Figure 1c–d) that the two tumor
incidence curves were separated over
the 17-week time course. We have
double checked our analyses and ver-
ified the log-rank tests. The P-values
(0.003 for Figure 1c and 0.01 for Figure
1d) were correct as reported in the
paper. These significant P-values
should not be surprising as even from
the graphs, it can be seen that the tumor
incidence curves were well separated
between Demabase and Water control
(Figure 1c), and between Dermovan
and Water control (Figure 1d).
RESPONSE TO ISSUE 6
As indicated, the numbers of tumors per
mouse (and tumor volume per mouse)
included mice with no tumors (counted
as ‘‘0’’, not ‘‘missing’’), as we and many
other investigators have performed in
earlier publications. It makes more bio-
logical sense to express the data as
described rather than as the number of
tumors per tumor-bearing mouse. The
conditional expression ‘‘given that at
least one tumor developed,’’ as sug-
gested by Dr Jewell, does not make bio-
logical sense. Expressing the data as we
have assesses total tumor load per group
(and takes into account the percentage
of mice with tumors and tumors per
tumor-bearing mouse). This approach is
also in line with the so-called ‘‘intention-
to-treat’’ principle of data from clinical
trials, that is, data analysis includes all
randomized subjects.
RESPONSE TO ISSUE 7
It is well known that the nature of the
counting data (number of tumors per
mouse) is suitable for the Poisson model
analysis and that it is more suitable than
the two-sample t-test, which is used for
continuous data. We should also point
out that the zeros (the mice with no
tumors) were not structural (by the
design of the experiments), but were
random zeros (by the observations).
Dr Jewell misunderstood the biological
experiment.
RESPONSE TO ISSUE 8
The two experiments were similar in
procedure, but were performed more
than 1 year apart, which represented
the scientific development of hypoth-
esis generation followed by the testing
and confirmation process. When the
two experiments are combined together
in one paper, the most appropriate way
to analyze the data is to make side-by-
side between-group comparisons in
each experiment separately. In experi-
ment 1 with Dermabase, we hoped
(and expected) that it would be non-
tumorigenic, so that we could use it as a
vehicle for a human study. As we have
indicated in the paper, experiment 1
was conducted first, as a pilot/initial
study, which, after we observed the
carcinogenic effect of Dermabase, led
us to hypothesize that other commonly
used moisturizing creams might have
the same adverse effect. The second
experiment was conducted to test this
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hypothesis and to search for a non-
tumorigenic cream. In the second ex-
periment, we used both an untreated
control group and a water-treated
control group. It should be pointed out
that it was inappropriate to compare
absolute values of tumors per mouse or
the other parameters between two
experiments that were performed at
different times, but it was appropriate
to compare the relative treatment ef-
fects between the two experiments. The
results were consistent between the two
experiments, in the sense that the
harmful effect of Dermabase compared
with the untreated group (or water-
treated group) was pointing in the same
direction in both experiments. If one
were to combine the results by combin-
ing the two independent P-values, the
indication of the harmful effect of
Dermabase would even be much
stronger. Our overall conclusion was
that there was good reproducibility for
the tumorigenic effect of Dermabase
between experiments 1 and 2.
RESPONSE TO ISSUE 9
Although Dr Jewell is right to point out
that the between-experiment difference
was clearly statistically significant,
meaning that the conditions (or ani-
mals) in the two experiments produced
noticeably different results, it should be
emphasized that the results were differ-
ent in absolute values but not in
the direction of Dermabase-induced
change. It is very common to observe
experiment-to-experiment variation in
absolute values for two experiments
that were performed at different times.
(This was not a random variation, as
Dr Jewell suggested). As long as the
direction of treatment effects is the same,
the conclusions may be deemed valid.
We did not combine the data per se,
as suggested by Dr Jewell, since, as
indicated above, experiment 1, was a
pilot study, which generated a (surpris-
ing) hypothesis for experiment 2. The
noticeable between-experiment varia-
tion in absolute values is not unusual,
and actually justifies our separate data
analyses for each experiment. As in-
dicated above, we could have com-
bined the results by combining the two
independent P-values. Using Fisher’s
method of combining independent
P-values, the indication of the harmful
effect of Dermabase would be even
stronger.
RESPONSE TO ISSUE 10
We did not include a detailed descrip-
tion of the statistical inference as sug-
gested by Dr Jewell, as our report is
a biological paper for a biomedical
science journal, not a statistical paper
for a statistical journal. For Dr Jewell’s
information, our final model is the linear
regression model with a first-order auto-
regressive correlation structure to ac-
count for the within-mouse correlation.
The covariates include treatment, time,
and treatment–time interaction. No ran-
dom effect terms were used in our final
model. No intercepts were included in
the model because there were no tumors
at time 0. Although no random effect
terms were included in our final model,
they were still under the general category
of a mixed effect model. We used the
term ‘‘mixed effect model’’ in the paper
since the SAS Proc Mixed procedure was
used for the analyses.
The first-order autoregressive corre-
lation structure was selected after com-
paring other types of correlation
structures using AIC (Akaike’s informa-
tion criterion) and BIC (Bayesian infor-
mation criterion). As there were no
random effect terms in the model, the
correlation structure refers solely to the
error term in the model. Dr Jewell
prefers to use the generalized estimat-
ing equations (GEE) with a ‘‘working’’
within-mouse correlation structure. But
GEE is best applied to large samples,
while our sample size was moderate.
We prefer the likelihood-based method
because it is more powerful for infer-
ence when the model is specified
correctly; for our well-behaved data
and the linear regression model without
a random effect term, we have easily
verified the model assumptions. The
GEE approach, while robust, is less
powerful and may not be as able to
detect differences as the full-likelihood
approach is when differences do exist.
Accordingly, the GEE approach may
yield false negative results.
RESPONSE TO ISSUE 11
As indicated above, we have used the
proper within-experiment control for
the evaluation of our data. We have
explained the rationale and justification
of using the combined water and
untreated groups as the control for
experiment 2. There is no justification
for using the untreated group of experi-
ment 1 as the benchmark (control) for
experiment 2. We reject Dr Jewell’s
suggested manipulation of the control
group. The statistical evaluation of our
data and abstract are correct as re-
ported. The uncertainty information of
the estimates was provided by the
standard errors of the mean values in
Tables 2–5.
RESPONSE TO ISSUE 12
We view Dr Jewell’s hypothesis that
differences between treatment groups
might be because of or driven by the
effects after at least one tumor has
occurred, rather than arising from tu-
merigenic effects during post-UVB
treatment, as highly unlikely and lack-
ing in supporting data. Although topical
application of a cream to an animal
with a single tumor may influence the
growth of that tumor, there is no data
indicating that the first tumor can
influence the effect of the cream on
the formation of other tumors – many of
which are distant from the original
tumor.
We indicated earlier that Kaplan–-
Meier’s method was used to analyze the
time to the first tumor appearance, and,
as indicated in the Materials and
Methods section as well as in the
footnote of Figure 1, the log-rank test
was used to compare the tumor-free
distributions between the treated and
the control groups. The P-values from
the log-rank tests were shown.
CONCLUDING COMMENT
Although Dr Jewell and earlier cor-
respondents associated with compa-
nies that make the creams described
in our paper have criticized our pub-
lication, we are confident that our
data, the statistical evaluations, and
the conclusions described in our
paper are correct. Our data demon-
strate that topical applications of
several commercially available moist-
urizing creams enhance tumorigenesis
in UVB-pretreated SKH-1 mice. There
is a need to determine whether the
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use of moisturizing creams would
enhance sunlight-induced skin cancer
in humans.
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